Elixirgentherapeutics
Baltimore, US · Delaware corporation · 2 known investors
Elixir Therapeutics develops therapies for rare diseases and aging-related conditions using proprietary technologies, including ZSCAN4 for telomere extension in stem cell therapies and Bobcat mRNA for delivering large genes. The company is advancing clinical candidates for telomere biology disorders and Duchenne muscular dystrophy.
BiotechLongevityMedical Devices
Founders & leadership
MK
Minoru KoChief Scientific Officer
AK
AKIHIRO KOExecutive Officer, Director
HK
HIROAKI KOBAYASHIDirector
JC
JEFFREY CLELANDDirector
TW
THOMAS WHITEDirector
SC
SHAUNA CALLAHANDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$4MraisedNov 2025 · 1 investors · BiotechnologyRule 506(b)
▶$4MraisedNov 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- HIROAKI KOBAYASHIDirector
- THOMAS WHITEDirector
- JEFFREY CLELANDDirector
- MINORU KODirector
- SHAUNA CALLAHANDirector
- AKIHIRO KOExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.6MraisedApr 2025 · 2 investors · BiotechnologyRule 506(b)
▶$3.6MraisedApr 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- AKIHIRO KOExecutive Officer, Director
- MINORU KODirector
- JEFFREY CLELANDDirector
- THOMAS WHITEDirector
- SHAUNA CALLAHANDirector
- HIROAKI KOBAYASHIDirector
- Offering amount
- $3.6M
- Amount sold
- $3.6M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$600KraisedFeb 2025 · 2 investors · BiotechnologyRule 506(b)
▶$600KraisedFeb 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- HIROAKI KOBAYASHIDirector
- JEFFREY CLELANDDirector
- AKIHIRO KOExecutive Officer, Director
- THOMAS WHITEDirector
- MINORU KODirector
- SHAUNA CALLAHANDirector
- Offering amount
- $600K
- Amount sold
- $600K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedDec 2023 · 1 investors · BiotechnologyRule 506(b)
▶$7MraisedDec 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Akihiro C KoExecutive Officer, Director
- Minoru S.H. KoDirector
- Hiroaki KobayashiDirector
- Thomas K. WhiteDirector
- Shauna CallahanDirector
- Jeffrey ClelandDirector
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5MraisedSep 2022 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedSep 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maiko KatadaeDirector
- Minoru KoExecutive Officer, Director
- Akihiro KoExecutive Officer, Director, Promoter
- Shauna CallahanDirector
- Hiroaki KobayashiDirector
- Thomas WhiteDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedFeb 2021 · 2 investors · BiotechnologyRule 506(b)
▶$4.2MraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Akihiro KoExecutive Officer, Director
- Minoru KoDirector
- Hiroaki KobayashiDirector
- Naonori KurokawaDirector
- Thomas WhiteDirector
- Shauna CallahanDirector
- Offering amount
- $5.5M
- Amount sold
- $4.2M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.7MraisedAug 2020 · 3 investors · BiotechnologyRule 506(b)
▶$5.7MraisedAug 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maiko KatadaeDirector
- Minoru KoDirector
- Akihiro KoExecutive Officer, Director
- Naonori KurokawaDirector
- Offering amount
- $5.7M
- Amount sold
- $5.7M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4MraisedJun 2018 · 1 investors · BiotechnologyRule 506(b)
▶$4MraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- AKIHIRO KOExecutive Officer, Director
- MINORU S.H. KODirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.